LTC1713458I2 - Ospemifeno bioaktyvumo padidinimo būdas - Google Patents

Ospemifeno bioaktyvumo padidinimo būdas

Info

Publication number
LTC1713458I2
LTC1713458I2 LTPA2015023C LTPA2015023C LTC1713458I2 LT C1713458 I2 LTC1713458 I2 LT C1713458I2 LT PA2015023 C LTPA2015023 C LT PA2015023C LT PA2015023 C LTPA2015023 C LT PA2015023C LT C1713458 I2 LTC1713458 I2 LT C1713458I2
Authority
LT
Lithuania
Prior art keywords
ospemifene
bioactivity
increase
way
compound
Prior art date
Application number
LTPA2015023C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Hormos Medical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1713458(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd. filed Critical Hormos Medical Ltd.
Publication of LTPA2015023I1 publication Critical patent/LTPA2015023I1/lt
Publication of LTC1713458I2 publication Critical patent/LTC1713458I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
LTPA2015023C 2004-02-13 2015-06-25 Ospemifeno bioaktyvumo padidinimo būdas LTC1713458I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
PCT/FI2005/000018 WO2005077350A1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (2)

Publication Number Publication Date
LTPA2015023I1 LTPA2015023I1 (lt) 2015-08-25
LTC1713458I2 true LTC1713458I2 (lt) 2017-06-26

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2015023C LTC1713458I2 (lt) 2004-02-13 2015-06-25 Ospemifeno bioaktyvumo padidinimo būdas

Country Status (23)

Country Link
US (5) US8236861B2 (enExample)
EP (1) EP1713458B1 (enExample)
JP (2) JP5577011B2 (enExample)
CN (1) CN1925847A (enExample)
AT (1) ATE387910T1 (enExample)
AU (1) AU2005211958B2 (enExample)
BE (1) BE2015C033I2 (enExample)
BR (1) BRPI0507661A (enExample)
CA (1) CA2556089C (enExample)
CY (2) CY1111014T1 (enExample)
DE (1) DE602005005165T2 (enExample)
DK (1) DK1713458T5 (enExample)
ES (1) ES2302177T3 (enExample)
FR (1) FR15C0041I2 (enExample)
HU (1) HUS1500030I1 (enExample)
LT (1) LTC1713458I2 (enExample)
LU (1) LU92736I2 (enExample)
MX (1) MXPA06009274A (enExample)
NO (2) NO337656B1 (enExample)
PL (1) PL1713458T3 (enExample)
PT (1) PT1713458E (enExample)
RU (1) RU2385716C2 (enExample)
WO (1) WO2005077350A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
MXPA06012758A (es) 2004-05-04 2007-01-16 Hormos Medical Ltd Novedosas formulaciones orales de ospemifeno.
EP1948148A2 (en) * 2005-11-09 2008-07-30 Hormos Medical Ltd. Formulations of fispemifene
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA018066B1 (ru) * 2005-11-28 2013-05-30 Джи Ти Икс, ИНК. Агент, связывающийся с ядерными рецепторами
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
BRPI0823326B1 (pt) * 2007-02-14 2021-06-29 Hormos Medical Ltd. Método para a preparação de um composto derivado de trifenilbuteno
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EP2909164A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
UA127229C2 (uk) 2018-05-11 2023-06-14 Ксенон Фармасьютікалз Інк. Спосіб збільшення біологічної доступності й ступеня впливу активатора потенціалзалежних калієвих каналів
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
BR112022008580A2 (pt) 2019-11-08 2022-08-09 Xenon Pharmaceuticals Inc Métodos para tratar transtornos depressivos
EP4291189A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US6219674B1 (en) * 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
CA2438816A1 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
JP4362442B2 (ja) 2002-06-06 2009-11-11 ホルモス メディカル リミテッド 女性における萎縮の抑制方法または萎縮関連症状の治療または予防方法
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
FR15C0041I2 (fr) 2015-11-13
US20120270952A1 (en) 2012-10-25
ATE387910T1 (de) 2008-03-15
US8236861B2 (en) 2012-08-07
RU2006132719A (ru) 2008-03-20
DK1713458T3 (da) 2008-07-07
CY1111014T1 (el) 2015-06-11
LU92736I2 (fr) 2015-08-10
EP1713458B1 (en) 2008-03-05
NO20063960L (no) 2006-11-03
JP5577011B2 (ja) 2014-08-20
BRPI0507661A (pt) 2007-07-17
AU2005211958B2 (en) 2010-11-25
NO20151603L (no) 2006-11-03
NO339190B1 (no) 2016-11-14
CY2015027I2 (el) 2016-04-13
US8772353B2 (en) 2014-07-08
JP2007522190A (ja) 2007-08-09
US20140303259A1 (en) 2014-10-09
NO337656B1 (no) 2016-05-23
US8470890B2 (en) 2013-06-25
CN1925847A (zh) 2007-03-07
WO2005077350A1 (en) 2005-08-25
US20050182143A1 (en) 2005-08-18
JP6023119B2 (ja) 2016-11-09
LTPA2015023I1 (lt) 2015-08-25
US9855224B2 (en) 2018-01-02
AU2005211958A1 (en) 2005-08-25
BE2015C033I2 (enExample) 2024-08-08
US9241915B2 (en) 2016-01-26
MXPA06009274A (es) 2007-04-16
PT1713458E (pt) 2008-05-07
US20160101065A1 (en) 2016-04-14
CA2556089A1 (en) 2005-08-25
CA2556089C (en) 2013-04-02
JP2014141533A (ja) 2014-08-07
RU2385716C2 (ru) 2010-04-10
HUS1500030I1 (hu) 2015-08-28
DE602005005165T2 (de) 2009-04-30
US20130324614A1 (en) 2013-12-05
ES2302177T3 (es) 2008-07-01
FR15C0041I1 (enExample) 2015-07-17
PL1713458T3 (pl) 2008-08-29
EP1713458A1 (en) 2006-10-25
DK1713458T5 (da) 2008-09-29
DE602005005165D1 (de) 2008-04-17
CY2015027I1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
LTPA2015023I1 (lt) Ospemifeno bioaktyvumo padidinimo būdas
CY1111689T1 (el) Στερεες φαρμακοτεχνικες μορφες ospemifene
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
EA200800147A1 (ru) Способ получения олмесартан медоксомила
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
EP2620145A3 (en) 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ
JP2011137005A5 (enExample)
AR051754A1 (es) Metodos para preparar compuestos de indazol
NO20082181L (no) Formuleringer av Fispemifen
IL181155A0 (en) 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i?á
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2009011901A3 (en) Methods for promoting wakefulness
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
WO2010047559A2 (ko) 방출성이 제어된 약제학적 제제
RU2004116385A (ru) Средство для коррекции уролого-андрологической патологии
UY30810A1 (es) Composicion farmacéutica en la forma de una capsula de gelatina, comprendiendo un acido famacéuticamente aceptable.
DK1765785T3 (da) Prostaglandinanaloger
BRPI0510465A (pt) formulação de droga oral semi-sólida ou lìquida
RU2004130744A (ru) Способ формирования повышенной судорожной готовности (киндлинга) у мышей
DE602005016711D1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen
EA200800281A1 (ru) Способ коррекции экспериментального миокардита с помощью мицеллярной формы интерферона альфа
RU2002109126A (ru) Способ химиопрофилактики гриппа
RU2004133858A (ru) Способ интраоперационной профилактики несостоятельности культи главного бронха после пневмонэктомии
MX2010000624A (es) Metodo para promover la vigilia.